Newsfeeds
Breaking World Pharma News
World Pharma News - one of the world's leading web-based pharmaceutical news publications - is committed to providing and disseminating the most prominent pharmaceutical news and achievements.

World Pharma News
  • Pfizer and Kyowa Hakko Kirin to collaborate on immuno-oncology combination study
    PfizerPfizer Inc. (NYSE:PFE) and Kyowa Hakko Kirin (Tokyo:4151), have entered into an agreement to explore the therapeutic potential of the combination of Pfizer's PF-05082566, an investigational, fully humanized monoclonal antibody (mAb) that stimulates signaling through 4-1BB (CD-137), a protein involved in regulation of immune cell activation, proliferation and survival, with Kyowa Hakko Kirin's anti-CCR4 antibody mogamulizumab,

  • Transplant drug could boost the power of brain tumor treatments
    Every day, organ transplant patients around the world take a drug called rapamycin to keep their immune systems from rejecting their new kidneys and hearts. New research suggests that the same drug could help brain tumor patients by boosting the effect of new immune-based therapies.

  • New research outlines promising therapies for small cell lung cancer
    Two recently published studies by a research team at University Hospitals (UH) Case Medical Center Seidman Cancer Center have the potential to advance treatments for small cell lung cell cancer (SCLC). This aggressive form of lung cancer has seen no treatment advances in 30 years and "is a disease in urgent need of new drug therapies," write the study's authors.

  • Novo Nordisk establishes new obesity research unit in Seattle
    Novo NordiskNovo Nordisk has announced that the company will establish a new obesity research unit in Seattle, Washington, in the US. The new unit is a result of Novo Nordisk's increasing focus on treatment of obesity. Its main task will be to identify novel approaches and targets for obesity treatments while increasing the scientific understanding of existing obesity targets.

  • Discrepancies in access to new cancer drugs revealed
    Access to potentially life-extending cancer drugs varies significantly in different regions of the world, two new studies show at the ESMO 2014 Congress in Madrid, Spain. Researchers say the results demonstrate the need for better collaboration between doctors and health authorities on an international scale, to ensure patients have access to the best treatments.

  • MedImmune and Cancer Research UK establish joint CRUK-MEDI Alliance Laboratory
    AstraZenecaAstraZeneca today announced that MedImmune, its global biologics research and development arm, and Cancer Research UK, with its commercial arm, Cancer Research Technology (CRT), have entered into an innovative collaboration to establish a joint laboratory in Cambridge, UK.

  • Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy
    Boehringer IngelheimBoehringer Ingelheim and CureVac, leader in mRNA (messenger ribonucleic acid)-based drug development, have announced an exclusive global license and development collaboration. The new collaboration focuses on CureVac's CV9202, a novel investigational therapeutic mRNA vaccine, in early clinical development for the treatment of lung cancer.

  • Stanford researchers create 'evolved' protein that may stop cancer from spreading
    A team of Stanford researchers has developed a protein therapy that disrupts the process that causes cancer cells to break away from original tumor sites, travel through the blood stream and start aggressive new growths elsewhere in the body. This process, known as metastasis, can cause cancer to spread with deadly effect.

  • Bristol-Myers Squibb and Pfizer announce charitable donations of more than $1 million to support cardiovascular education
    Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced charitable donations totaling more than $1 million to be granted between 2014 and 2016 to seven nonprofit organizations that support patients with cardiovascular disease.

  • Merck to acquire Sigma-Aldrich to enhance position in attractive life science industry
    Merck KGaAMerck, a leading company for innovative and top-quality high-tech products in the pharmaceutical, chemical and life science sectors, and Sigma-Aldrich today announced that they have entered into a definitive agreement under which Merck will acquire Sigma-Aldrich for $17.0 billion (€13.1 billion), establishing one of the leading players in the $130 billion global life science industry.